The article linked below could be talking about a blood cancer called multiple myeloma as easily as it is talking about mantle cell lymphoma.
Both blood cancers affect the same age group (65-70), both blood cancers have a five-year survival rate of 48%-50% and according to the article below both blood cancers respond to lenalidomide aka Revlimid. Autologous stem cell transplantation is also a common therapy for each cancer.
Which is why the study below caught my eye. I am both a long-term MM survivor and cancer coach. Study after study for these two blood cancers plays down the importance of collateral damage aka side effects. Not only do I live with a host of side effects incurred during my years of conventional therapies, I have remained in CR from my MM by living an evidence-based, non-toxic, anti-MM lifestyle.
I’m not saying that the newly diagnosed CML patient should ignore conventional (FDA approved) therapies. I am saying that nutrition, supplementation, and lifestyle can enhance chemotherapy while moderating toxicity.
Please watch the free webinar linked on the right side of this page. If you have any questions or comments please scroll down the page and post a question or comment. I will reply to you ASAP.
“Lenalidomide (Revlimid) plus rituximab (Rituxan) is a feasible combination that is also safe and active, as initial and maintenance therapy for patients with mantle cell lymphoma (MCL),..